MedTrace Logo

Phase 1 Study of NPT200-11 in Healthy Subjects

NCT02606682 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2016-02-15

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, tolerability and blood levels of orally administered NPT200-11 in healthy subjects. In addition, the maximally tolerated dose will be determined.

Conditions

  • Healthy Volunteers

Interventions

DRUG

NPT200-11

Single doses of NPT200-11capsules, orally administered

DRUG

Placebo

Single doses of microcrystalline cellulose capsules, orally administered

Sponsors & Collaborators

  • UCB S.A. - Pharma Sector

    collaborator INDUSTRY

  • Neuropore Therapies Inc.

    lead INDUSTRY

Principal Investigators

  • Danielle Armas, M.D. CPI · Celerion

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02606682 on ClinicalTrials.gov